Sickle Cell Disease Treatment Market Size & Share 2023 to 2032
Market Size by Treatment Modality [Blood Transfusion, Pharmacotherapy (Hydroxyurea, Oxybryta, Endari), Bone Marrow Transplant], by Disease (Sickle Cell Anemia, Hemoglobin Sickle C), by End User & Forecast.
Report ID: GMI5697
|
Published Date: May 2023
|
Report Format: PDF
Download Free PDF
Authors:
Monali Tayade, Jignesh Rawal
Sickle Cell Disease Treatment Market Size
Sickle Cell Disease Treatment Market size surpassed USD 2.38 billion in 2022 and is anticipated to exhibit lucrative CAGR of around 12.6% between 2023 and 2032. The growth is attributed to factors such as the growing prevalence of sickle cell diseases, increasing R&D activities regarding sickle cell disease treatment, and increasing healthcare expenditure and government initiatives.
Sickle Cell Disease Treatment Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
Sickle cell disease is the most common inherited red blood cell disorder. It affects the oxygen-carrying protein haemoglobin, which is present in the blood. People with sickle cell disease inherit two faulty haemoglobin genes, known as haemoglobin S, from their parents. Usually, the red blood cells are round and flexible for easy passage through blood vessels. In the case of sickle cell disease, the red blood cells change their shape to resemble a crescent moon or sickle. These sickle cells become sticky and rigid and cause slow blood flow or may block the blood flow.
The management of sickle cell disease aims to avoid pain episodes, relieve the symptoms associated with the disease, and prevent complications. The treatment includes blood transfusions, medications, and bone marrow transplants.
COVID-19 Impact
During COVID-19, the global sickle cell disease treatment industry was obstructed due to the lockdown and travel restrictions imposed by the government all over the globe. Due to this, the number of people opting for sickle cell disease treatment and the number of hospitalizations decreased, hampering the sickle cell disease treatment market. For instance, in 2020, according to the Community Survey Report published by the National Organization of Rare Disorders (NORD) in the U.S., 74% of the 772 participants in the survey who suffered from a rare disease had cancelled their medical appointments due to travel restrictions and in order to avoid in-person contact. Later, as COVID instances decreased, the market experienced considerable growth as there was an increase in the number of patients opting for the treatments and new product launches.
Sickle Cell Disease Treatment Market Trends
The prevalence of sickle cell disease is increasing worldwide and significantly impacting the global market growth. According to the data presented by the WHO, in 2022, more than 66% of the 120 million people affected by sickle cell disease were from Africa. In Africa, 1,000 children are born with the disease every day. In Africa, in 2019, approximately 38403 deaths were recorded due to sickle cell disease. The high prevalence of this disease increases the demand for treatment options like blood infusions, pharmacotherapy, and bone marrow transplants. A high prevalence of sickle cell disease is reported in Africa, the Middle East, and India. The prevalence of sickle cell disease is increasing in other geographies along with migration.
Due to the increasing prevalence of sickle cell disease, pharmaceutical and biotechnology companies have increased their investment in R&D in order to develop new treatment options to treat various forms of sickle cell disease, such as sickle cell anemia, hemoglobin sickle C disease, and others. The increasing initiatives by government and private organizations for the treatment of sickle cell disease will drive the market in the coming years. For instance, in 2022, according to the data published by WHO, African health ministers have launched a campaign to increase awareness, bolster prevention, and provide care to reduce the toll of sickle cell disease, which is one of the most common diseases in this region.
Thus, pharmaceutical companies have increased research activities for the development of new sickle cell disease treatment products. The improved healthcare infrastructure, increasing healthcare expenditures, and R&D funding will propel the growth of this market.
Sickle Cell Disease Treatment Market Analysis
Based on treatment modality, the global sickle cell disease treatment market is subdivided into blood transfusion, pharmacotherapy, and bone marrow transplant. Pharmacotherapy is further subdivided on the basis of drug type and route of administration. On the basis of drug type, pharmacotherapy is classified into Hydroxyurea, Oxybryta, Adakveo, Endari, and other pharmacotherapies.
The blood transfusion segment dominated the market in 2022 with a revenue share of 65.1%. For sickle cell disease, blood transfusion has been considered the most effective treatment option to treat severe symptoms like strokes. Due to the rising number of episodes of stroke in sickle cell anemia patients, the demand for blood transfusion treatment has increased. Moreover, during the forecast period, the pharmacotherapy segment is anticipated to grow at a significant CAGR. Factors such as the introduction of new branded pharmacotherapy drugs, a strong pipeline, and increasing R&D activities fuel the market demand.
On the basis of drug type, the market for pharmacotherapy is subdivided into Hydroxyurea, Oxybryta, Adakveo, Endari, and other pharmacotherapies. Hydroxyurea segment dominated the market in 2022 and is expected to display significant growth. Hydroxyurea is an ideal drug for sickle cell disease patients by reducing the pain crisis and need for blood transfusion, due to which the demand and utilization of hydroxyurea are rising.
On the basis of route of administration, the market for pharmacotherapy is subdivided into oral and parenteral. The oral segment held the highest market share in 2022 owing to high adoption, non-invasiveness, patient compliance, and convenience. Many of the pharmacotherapy drugs are administered orally; for instance, hydroxyurea or Endari are available in tablet form.
Based on disease type, the global sickle cell disease treatment market is classified into sickle cell anemia, hemoglobin sickle C disease (HbSC), and other disease types. The sickle cell anemia segment accounted for the largest share in 2022 due to the high prevalence of sickle cell anemia. It is the most common and severe form of sickle cell disease, and the increasing complications associated with sickle cell anemia such as hemolysis or vaso-occlusive crises, are factors contributing to the growth of this segment.
Based on end-user, the global sickle cell disease treatment market is subdivided into hospitals, specialty clinics, and other end-users. Among the end-user segments, the hospital segment held the highest revenue share of the market in 2022. The increasing prevalence of sickle cell disease, development of new therapies for treating sickle cell disease, increasing government initiatives in launching the new drugs and increased number of admissions for sickle cell disease in hospitals accelerated the growth of this segment.
In 2022, the North America held the highest revenue in this market, owing to an increased prevalence of sickle cell diseases, increasing investments for R&D for developing new drugs for treating sickle cell disease, presence of key players, and well-developed healthcare infrastructure. During the forecast period, Asia Pacific segment is anticipated to witness significant growth due to the increasing prevalence of sickle cell disease and increased government initiatives and fundings.
In North America segment, U.S. accounted for the highest market share in 2022 due to the better access to treatment options, strong promising pipeline drugs, increasing number of product launches, acquisitions and increasing awareness and demand for sickle cell disease treatment.
Sickle Cell Disease Treatment Market Share
The key players in sickle cell disease treatment market are :
These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches, etc. to maintain a competitive edge in the industry.
Sickle Cell Disease Treatment Industry News:
The sickle cell disease treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032 for the following segments:
Click here to Buy Section of this Report
By Treatment Modality
By Disease Type
By End-user
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →